Strategic Global Advisors’s AstraZeneca AZN Stock Holding History

Strategic Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	6,683 +2,579	+63%	+$485K	0.16%	105
2026 Q1	$809K	Sell	4,104 -949	-19%	-$183K	0.13%	122
2025 Q4	$929K	Buy	5,053 +3,398	+205%	+$596K	0.14%	114
2025 Q3	$254K	Buy	1,655 +41	+3%	+$6.21K	0.04%	131
2025 Q2	$226K	Buy	1,614 +156	+11%	+$21.9K	0.04%	138
2025 Q1	$214K	Sell	1,458 -3,164	-68%	-$458K	0.04%	137
2024 Q4	$606K	Sell	4,622 -424	-8%	-$59.4K	0.11%	112
2024 Q3	$786K	Buy	5,046 +2,569	+104%	+$415K	0.15%	110
2024 Q2	$723K	Sell	2,477 -2,272	-48%	-$342K	0.15%	108
2024 Q1	$643K	Buy	+4,749	New	+$629K	0.14%	111
2021 Q4	–	Sell	-13,538	Closed	-$1.63M	–	140
2021 Q3	$1.63M	Buy	+13,538	New	+$1.58M	0.24%	110

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Strategic Global Advisors's AZN Position: Q2 2026 in Review

Strategic Global Advisors increased its AstraZeneca (AZN) stake by 63% in Q2 2026, buying an estimated $485K and bringing the position to 6,683 shares worth $1.16M. The position accounts for 0.16% of the portfolio, ranked #105.

Strategic Global Advisors first reported a position in AZN in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.63M in Q3 2021. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Strategic Global Advisors held 6,683 shares of AstraZeneca worth $1.16M as of Q2 2026.
Strategic Global Advisors bought 2,579 AstraZeneca shares in Q2 2026, an estimated $485K.
AstraZeneca made up 0.16% of Strategic Global Advisors's portfolio in Q2 2026, its #105 holding.
Strategic Global Advisors first reported a position in AstraZeneca in Q3 2021 and has held it in 11 quarters since.
Strategic Global Advisors's AstraZeneca position peaked at $1.63M in Q3 2021.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Strategic Global Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.